How the drug used for intubation affects early survival in critically ill adults
Association of Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients: A Large-Scale Retrospective Cohort Analysis
This retrospective review looks at adults in the surgical ICU to see if the induction drug given for tracheal intubation is linked to early death and other complications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Umraniye Education and Research Hospital Government |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT07222007 on ClinicalTrials.gov |
What this trial studies
This retrospective cohort study reviews medical records of adults admitted to the surgical ICU at UF Health Jacksonville who underwent tracheal intubation. It compares outcomes after different induction agents (for example, propofol, midazolam, etomidate, and ketamine), with primary focus on early mortality and peri-intubation hemodynamic instability. Inclusion requires age ≥18, documented administration of one of the studied induction agents, and complete clinical data, while records with missing documentation are excluded. Multivariable analyses will control for baseline illness severity and other confounders to estimate associations between induction choice and outcomes.
Who should consider this trial
Good fit: Adults (≥18 years) admitted to the surgical ICU who underwent tracheal intubation with a documented induction agent and complete medical records.
Not a fit: Children, patients intubated outside the surgical ICU, and cases with undocumented induction agents or incomplete records are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If one induction agent is associated with lower early mortality or fewer complications, clinicians could preferentially use that agent to improve safety during intubation.
How similar studies have performed: Large observational cohorts (for example INTUBE) have described common agent use, but systematic reviews report that current evidence is still insufficient to declare a best induction agent for minimizing cardiovascular instability.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Admission to the surgical ICU for critical care * Administration of one of the studied induction agents * Availability of complete clinical data Exclusion Criteria: * Age \< 18 years * Absence of documented induction agent administration * Incomplete or missing medical records
Where this trial is running
Jacksonville, Florida
- UF Health Jacksonville (Shands Hospital) — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: TOLGA SARAÇOĞLU, Prof,MD — Florida University Jacksonville
- Study coordinator: TOLGA SARAÇOĞLU, Prof,MD
- Email: kemaltolgasaracoglu@gmail.com
- Phone: +1 (904) 524-5932
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.